Tw. Robbins et al., COGNITIVE ENHANCERS IN THEORY AND PRACTICE - STUDIES OF THE CHOLINERGIC HYPOTHESIS OF COGNITIVE DEFICITS IN ALZHEIMERS-DISEASE, Behavioural brain research, 83(1-2), 1997, pp. 15-23
The current status of the cholinergic hypothesis of cognitive dysfunct
ion in Alzheimer's disease is reviewed in the context of recent attemp
ts to alleviate specific cognitive impairments produced in rats by exc
itotoxic lesions of basal forebrain neurons by treatment with choliner
gic agents. AMPA-induced lesions of the nucleus basalis region in rats
produce profound and relatively specific reductions in neocortical ma
rkers of cholinergic function but fail to affect performance in many t
ests of memory and learning in rats. However, such lesions produce spe
cific deficits in responding accurately in a test of visual attentiona
l performance, which are reversed dose-dependently by treatment with s
ystemic physostigmine or nicotine. Analogous improvements have been re
ported in a clinical trial of the anticholinesterase tacrine in patien
ts with Alzheimer's disease. By contrast, AMPA-induced lesions of the
medial septum produce profound reductions in hippocampal acetylcholine
and accompanying delay-dependent deficits in a delayed non-matching-t
o-position procedure which measures spatial working memory in rats. Th
is impairment is shown to be reversed to some extent by treatment with
low doses of physostigmine. The results are discussed in terms of the
multivariate nature of the neurochemical pathology of Alzheimer's dis
ease and attendant limitations in the use of the cholinergic strategy.
The cognitive costs, as well as benefits, of cognitive enhancers are
discussed, as well as the need to broaden our therapeutic approach to
other neurotransmitter systems and other neurodegenerative disorders.